Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2015

01-08-2015 | Thoracic Oncology

Prognostic Significance of 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Authors: Takushi Yasuda, M.D., Masahiko Yano, M.D., Hiroshi Miyata, M.D., Makoto Yamasaki, M.D., Shuji Takiguchi, M.D., Yoshiyuki Fujiwara, M.D., Yuichiro Doki, M.D.

Published in: Annals of Surgical Oncology | Issue 8/2015

Login to get access

Abstract

Purpose

Patients with resectable thoracic esophageal squamous cell cancer (TESCC) and positron emission tomography (PET)-positive lymph nodes (PET-N positive) are likely to have ≥3 pathological lymph node metastases (pLNMs) and show a higher rate of postoperative recurrence despite curative resection than PET-N-negative TESCC patients. We examined the prognostic significance of 18F-fluorodeoxyglucose uptake into lymph node metastases after neoadjuvant chemotherapy (NAC) for PET-N positive TESCC and aimed to propose the optimal NAC response criteria for these patients.

Methods

Fifty-one patients with PET-N positive TESCC underwent two courses of NAC followed by surgery. Metabolic responses of primary tumors and LNs were prospectively evaluated and associations with clinicopathological data and patient survival assessed by univariate and multivariate analyses.

Results

After NAC, 21 patients were post-treatment (post-) PET-N positive and 30 post-PET-N negative. A significantly (p < 0.001) high proportion of the post-PET-N-negative group had ≤2 pLNMs than the post-PET-N positive group (86.7 vs. 28.6 %). The PET-N negative group also had a significantly lower distant metastasis rate (23.3 vs. 75.0 %) and higher 5-year relapse-free survival (RFS) rate (69.0 vs. 20.0 %). Univariate and multivariate Cox’s proportional hazard regression analyses identified post-PET-N negative status as the only significant favorable predictive factor for low postoperative recurrence (p = 0.015) independent of the primary tumor response.

Conclusions

PET-N negative status predicts ≤2 pLNMs and longer RFS in resectable TESCC patients even after NAC. Therefore, post-PET-N status, not the effects on the primary tumor, is a critical NAC treatment response criterion for evaluating prognosis and guiding subsequent treatment.
Appendix
Available only for authorised users
Literature
1.
Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg. 2000;87:1426–33.PubMedCrossRef
2.
Nakagawa S, Kanda T, Kosugi S, et al. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.PubMedCrossRef
3.
Kunisaki C, Makino H, Kimura J, et al. Impact of lymph-node metastasis site in patients with thoracic esophageal cancer. J Surg Oncol. 2010;101:36–42.PubMedCrossRef
4.
Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22:1–8.PubMedCrossRef
5.
Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction. Data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union against Cancer cancer staging manuals. Cancer. 2010;116:3763–73.PubMedCrossRef
6.
Yasuda T, Higuchi I, Yano M, et al. The impact of 18F-fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:652–60.PubMedCrossRef
7.
Yasuda T, Yano M, Miyata H, et al. Systemic control and evaluation of the response to neoadjuvant chemotherapy in resectable thoracic esophageal squamous cell carcinoma with 18F-fluorodeoxyglucose positron emission tomography-positive lymph nodes. Surg Today. 2014 Jun 27; [Epub ahead of print]. Accessed 27 June 2014. doi:10.​1007/​s00595-014-0956-7.
8.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef
9.
WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979.
10.
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–14.PubMedCrossRef
11.
Komori T, Doki Y, Kabuto T, et al. Prognostic significance of the size of cancer nests in metastatic lymph nodes in human esophageal cancers. J Surg Oncol. 2003;82:19–27.PubMedCrossRef
12.
Aguirre ACR, Ramos-Font C, Portero RV, et al. 18F-fluorodeoxyglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer. systematic review of the literature. Ann Surg. 2009;250:247–54.CrossRef
13.
Omloo JMT, van Heijl M, Hoekstra OS, et al. FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol. 2011;18:3338–352.PubMedCentralPubMedCrossRef
14.
Wong R, Walker-Dilks C, Raifu A. Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer. Clin Oncol. 2012;24:86–104.CrossRef
15.
Akutsu Y, Shuto K, Kono T, et al. The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. J Surg Oncol. 2012;105:756–60.PubMedCrossRef
16.
Castoro C, Scarpa M, Cagol M, et al. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution. Ann Surg Oncol. 2011;18:3743–54.PubMedCrossRef
17.
Sobin LH, Wittekind C, eds. TNM classification of malignant tumors, 6th edn. New York: Wiley; 2002.
18.
Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging manual, 6th edn. New York: Springer; 2002.
19.
Fukunaga H, Sekimoto M, Tatsumi M, et al. Clinical relevance of fusion images using (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography in local recurrence of rectal cancer. Int J Oncol. 2002;20:691–5.PubMed
20.
Paul AK, Tatsumi M, Higuchi I, et al. Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer. Nucl Med Commun. 2003;24:963–70.PubMedCrossRef
21.
Higuchi I, Yasuda T, Yano M, et al. Lack of fluorodeoxyglucose F18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2008;136:205–12.PubMedCrossRef
22.
Akita H, Doki Y, Miyata H, et al. Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol. 2006;93:401–9.PubMedCrossRef
23.
Shiozaki H, Yano M, Tsujinaka T, et al. Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer. Dis Esophagus. 2001;14:191–6.PubMedCrossRef
24.
Miyata H, Yano M, Doki Y, at al. A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intra-operative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes. J Surg Oncol. 2006;93:477–84.
25.
The Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: part I. Esophagus. 2009;6:1–25.CrossRef
26.
Dhar DK, Hattori S, Tonomoto Y, et al. Appraisal of a revised lymph node classification system for esophageal squamous cell cancer. Ann Thorac Surg. 2007;83:1265–72.PubMedCrossRef
27.
Gillies RS, Middleton MR, Han C, et al. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma. Br J Surg. 2012;99:239–45.PubMedCrossRef
Metadata
Title
Prognostic Significance of 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Authors
Takushi Yasuda, M.D.
Masahiko Yano, M.D.
Hiroshi Miyata, M.D.
Makoto Yamasaki, M.D.
Shuji Takiguchi, M.D.
Yoshiyuki Fujiwara, M.D.
Yuichiro Doki, M.D.
Publication date
01-08-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 8/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4299-9

Other articles of this Issue 8/2015

Annals of Surgical Oncology 8/2015 Go to the issue

Reconstructive Oncology

Immediate Reconstruction of the Radiated Breast: Recent Trends Contrary to Traditional Standards

Breast Oncology

Surgical Management of Multifocal and Multicentric Breast Cancers: Can We Achieve the Same, with Less?

Breast Oncology

A Patient-Centered Approach to Wait Times in the Surgical Management of Breast Cancer in the Province of Ontario

Endocrine Tumors

Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group

Breast Oncology

Omentum for Mammary Disorders: A 30-Year Systematic Review

Urologic Oncology

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus